<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301378</url>
  </required_header>
  <id_info>
    <org_study_id>09-956 KeraSys</org_study_id>
    <nct_id>NCT01301378</nct_id>
  </id_info>
  <brief_title>Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube</brief_title>
  <official_title>Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IOP Ophthalmics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that KeraSys is a safe as Tutoplast to cover the tube of the
      Molteno 3 glaucoma drainage device during surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares patients who will undergo Molteno 3 shunt implant surgery with 1 group
      receiving KeraSys patch graft and the 2nd group receiving Tutoplast patch graft. The
      investigators will examine the efficacy and safety of KeraSys in comparison with Tutoplast
      and monitor the long term effectiveness for preventing tube erosion in Molteno 3 tube shunt
      surgery for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    kerasys had more erosions than tutoplast
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kerasys safety</measure>
    <time_frame>one day, week one, 1 month, 3 month, 6 month, and 1 year</time_frame>
    <description>The patch graft will be graded on appearance at each visit by slit lamp for tube erosion and conjunctival retraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy of Kerasys and Tutoplast in Molteno 3 glaucoma shunt surgery</measure>
    <time_frame>1 month, 3 month, 6 month, 1 year</time_frame>
    <description>The thickness of the patch graft will be measured by anterior segment OCT and anterior segment photos.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Primary Angle Closure Glaucoma</condition>
  <condition>Pseudoexfoliation Glaucoma</condition>
  <condition>Pigmentary Glaucoma</condition>
  <condition>Traumatic Glaucoma</condition>
  <condition>Uveitic Glaucoma</condition>
  <condition>Neovascular Glaucoma</condition>
  <arm_group>
    <arm_group_label>KeraSys Tissue Patch Graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tutoplast tissue patch graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Molteno 3 glaucoma drainage shunt</intervention_name>
    <description>Patients needing glaucoma drainage surgery</description>
    <arm_group_label>KeraSys Tissue Patch Graft</arm_group_label>
    <arm_group_label>Tutoplast tissue patch graft</arm_group_label>
    <other_name>Porcine Submucosal Tissue Patch Graft (Kerasys)</other_name>
    <other_name>Processed Pericardium Patch Graft (Tutoplast)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with primary open-glaucoma (POAG), primary angle-closure glaucoma (PACG),
        pseudoexfoliation, pigmentary, traumatic, uveitic or neovascular glaucoma

        Exclusion Criteria:

          1. Age â‰¤ 18 years old.

          2. Any type of glaucoma other than those listed in the inclusion criteria.

          3. Less than 3 months of other ocular surgery.

          4. Active thyroid-related immune orbitopathy, carotid-cavernous fistula, Sturge Weber
             syndrome, orbital tumors or orbital congestive disease.

          5. Patients with connective tissue disorder.

          6. Patients with congenital or developmental glaucoma.

          7. Patients with severe dry eye syndrome.

          8. Patients with any surgical procedure involving revision, removal, or change of the
             existing glaucoma tube shunt.

          9. Patients undergoing any surgical concomitant surgical procedure involving the
             posterior segment.

         10. Patients with active scleritis, history of ocular trauma including chemical burn,
             chronic ocular inflammatory disease, or ocular surface disease.

         11. Patients with any prior history of allergy to the active compound.

         12. Pregnancy or breast-feeding.

         13. Patients enrolled in other prospective clinical trials.

         14. Patients that plan to use contact lens after surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene M Moster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute Glaucoma Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lankaranian D, Reis R, Henderer JD, Choe S, Moster MR. Comparison of single thickness and double thickness processed pericardium patch graft in glaucoma drainage device surgery: a single surgeon comparison of outcome. J Glaucoma. 2008 Jan-Feb;17(1):48-51. doi: 10.1097/IJG.0b013e318133fc49.</citation>
    <PMID>18303385</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Marlene Moster, MD</investigator_full_name>
    <investigator_title>Marlene Moster, MD Principal Investigator, Wills Eye Institute Glaucoma Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

